17 withdrawn. 17 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Withdrawn 17 |
| Phase 1 | 5 | Withdrawn 5 |
Follow Adenoma: new trials by email Literature Review of Adenoma trials Research Report on Adenoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma alrizomadlin - Mesothelioma, Malignant Mesothelioma (MM) | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2026-03-16 | 2026-03-17 | |
| Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss Milademetan, Atezolizumab - Advanced Solid Tumor, CDKN2A | Phase 1 / Phase 2 | Withdrawn | Rain Oncology Inc | 2023-05-19 | 2023-10-19 | |
| Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers Regorafenib in combination with Tislelizumab - Anal Squamous Cell Carcinoma, Colorectal Neoplasms | Phase 2 | Withdrawn | Translational Research in Oncology | 2023-04-30 | 2023-06-07 | |
| Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver cytoreductive surgery, Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT), Peptide receptor radionuclide therapy (PRRT) - Pancreatic Neuroendocrine Tumor, Pancreas Cancer | Phase 1 / Phase 2 | Withdrawn | University of Chicago | 2023-03-07 | 2024-10-26 | |
| 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs 177Lu-DOTATOC - Neuroendocrine Tumors, Carcinoid Tumor | Phase 2 | Withdrawn | British Columbia Cancer Agency | 2023-01-15 | 2023-02-21 | |
| A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma Atezolizumab - Malignant Pleural Mesothelioma, Advanced, Malignant Pleural Mesothelioma, Unresectable | Phase 2 | Withdrawn | Health Pharma Professional Research | 2020-08-01 | 2021-05-13 | |
| Pasireotide in Hyperinsulinemic Hypoglycemia Pasireotide 0.6Mg Solution for Injection, Saline Solution - Congenital Hyperinsulinism, Insulinoma | Phase 2 | Withdrawn | Montefiore Medical Center | 2017-04-01 | 2021-05-14 | |
| A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients Pembrolizumab, CDX-1401, Poly-ICLC - Non Small Cell Lung Cancer, Advanced Triple Negative Breast Cancer | Phase 1 / Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2017-01-01 | 2016-12-07 | |
| Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors dovitinib lactate, pharmacological study, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2014-10-01 | 2017-07-19 | |
| Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies Radiation, Panitumumab - Adenoma, Pleomorphic, Mixed Salivary Gland Tumor | Phase 2 | Withdrawn | University of Pittsburgh | 2011-08-01 | 2016-01-08 | |
| AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma rilotumumab, cisplatin, pemetrexed disodium - Advanced Malignant Mesothelioma, Epithelial Mesothelioma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2010-04-01 | 2013-08-02 | |
| Temozolomide in Treating Patients With Invasive Pituitary Tumors temozolomide, DNA methylation analysis, microarray analysis - Brain and Central Nervous System Tumors | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2009-12-01 | 2020-07-31 | |
| A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin - Mesothelioma | Phase 1 / Phase 2 | Withdrawn | University of Southern California | 2008-04-01 | 2014-05-21 | |
| Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients curcumin - Familial Adenomatous Polyposis | Phase 2 | Withdrawn | Johns Hopkins University | 2005-11-01 | 2012-09-20 | |
| Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors octreotide acetate, vatalanib, anti-cytokine therapy - Gastrointestinal Carcinoid Tumor, Islet Cell Carcinoma | Phase 2 | Withdrawn | Eastern Cooperative Oncology Group | 2015-10-08 | ||
| Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy antineoplaston A10, antineoplaston AS2-1, alternative product therapy - Merkel Cell Carcinoma, Islet Cell Carcinoma | Phase 2 | Withdrawn | Burzynski Research Institute | 2013-07-10 | ||
| A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma Cisplatin, Pemetrexed, Vorinostat - Malignant Pleural Mesothelioma | Phase 1 / Phase 2 | Withdrawn | University College, London | 2012-03-22 |
Mesothelioma (5) · Mesothelioma, Malignant (5) · Insulinoma (4) · Carcinoma, Islet Cell (3) · Gastrinoma (3) · Somatostatinoma (3) · Glucagonoma (2) · Growth Hormone-Secreting Pituitary Adenoma (2) · Melanoma (2) · Pituitary Neoplasms (2) · Small Cell Lung Carcinoma (2) · Vipoma (2) · Adenoma, Acidophil (1) · Adenoma, Basophil (1) · Adenoma, Chromophobe (1)
Neoplasms by Histologic Type (17) · Neoplasms, Glandular and Epithelial (17) · Neoplasms (16) · Neoplasms by Site (15) · Digestive System Diseases (9) · Digestive System Neoplasms (9) · Neoplasms, Mesothelial (8) · Endocrine Gland Neoplasms (7) · Endocrine System Diseases (7) · Neoplasms, Germ Cell and Embryonal (7) · Neuroectodermal Tumors (7) · Lung Diseases (6) · Lung Neoplasms (6) · Neuroendocrine Tumors (6)
Cisplatin (3) · Pemetrexed (3) · Biological Therapy (2) · atezolizumab (2) · 177Lu-octreotide, DOTA(0)-Tyr(3)- (1) · 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (1) · Complementary Therapies (1) · Curcumin (1) · Cytoreduction Surgical Procedures (1) · DNA Methylation (1) · Injections (1) · Microarray Analysis (1) · Octreotide (1) · Panitumumab (1) · Radiation (1)
National Cancer Institute (NCI) (2) · Academic and Community Cancer Research United (1) · British Columbia Cancer Agency (1) · Burzynski Research Institute (1) · Case Comprehensive Cancer Center (1) · Eastern Cooperative Oncology Group (1) · Health Pharma Professional Research (1) · Johns Hopkins University (1) · Jonsson Comprehensive Cancer Center (1) · Montefiore Medical Center (1) · Rain Oncology Inc (1) · Translational Research in Oncology (1) · University College, London (1) · University of Chicago (1) · University of Pittsburgh (1)
United States (5) · Canada (1) · Mexico (1)
Anthony Heaney, MD (1) · Barbara Gitlitz, MD (1) · David S Schrump, M.D. (1) · Dean Fennell (1) · Emily Bergsland (1) · Erika Brutsaert, M.D., M.P.H. (1) · Francis M Giardiello, M.D. (1) · Francois Benard, MD (1) · James Stevenson (1) · Jorge Arturo Alatorre Alexander, MD (1) · Josep Tabernero (1) · Kyle Holen, MD (1) · Mary Mulcahy, MD (1) · Michael K. Gibson, MD (1) · Stanislaw R. Burzynski, MD, PhD (1)
2009 (1), U10CA021115 (1)